EpiEndo

Lungs
#Chronic obstructive pulmonary disease (COPD) #EpiEndo #Non-antibiotic macrolides #Phase II trial

Positive results announced for COPD therapy

Biopharmaceutical company EpiEndo has completed a Phase IIA clinical trial for its therapy addressing chronic obstructive pulmonary disease (COPD). EpiEndo is developing orally available, non-antibiotic macrolides, or Barriolides, that reduce inflammation while also limiting antimicrobial resistance (AMR). The company’s lead asset is EP395 and it focuses… Read More

#News